Drug Details
| General Information of the Drug (ID: DR8051) | ||||
|---|---|---|---|---|
| Name |
Quinidine
|
|||
| Synonyms |
quinidine; 56-54-2; (+)-Quinidine; Conchinin; Chinidin; Pitayine; Quinidex; beta-Quinine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; Cin-Quin; Conquinine; Kinidin; Conchinine; chinidinum; quinidina; Quiniduran; Chinidine; Cinchonan-9-ol, 6'-methoxy-, (9S)-; UNII-ITX08688JL; Quinaglute; Auriquin; Quinidine sulfate; CHEBI:28593; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol; MFCD00135581; Quinicardine; CHEMBL1294; Cardioquin; Duraquin; Quinact; Quinalan; Quinatime; (1S)-(6-Methoxyquinolin-4-yl)((2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; Quinidine hydrochloride monohydrate; ITX08688JL; 6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; beta-Quinidine; (3'.alpha., 9S)-6'-Methoxycinchonan-9-ol; Quinidine, 98%, anhydrous; TCMDC-131239; NCI-C56246; (8R,9S)-6'-Methoxycinchonan-9-ol; (R)-(6-methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol; (S)-(6-methoxy-4-quinolyl)-[(2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol; (S)-[(4S,5R,7R)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol; Chinidin [German]; SMR000857275; Quinidine [BAN:NF]; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; Quinindine; CCRIS 672; HSDB 225; (S)-(6-methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; QDN; EINECS 200-279-0; Quinidine, anhydrous; PubChem7994; Prestwick3_000280; bmse000511; Epitope ID:141803; SCHEMBL15943; BSPBio_000160; MLS001335913; MLS001335914; MLS002548869; BPBio1_000176; GTPL2342; DTXSID4023549; SCHEMBL17537608; HMS2234L10; HMS3259O09; ACT09863; HY-B1751; ZINC3831405; (9S)-6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol (9S)-; BDBM50121975; RW2069; AKOS015920101; CCG-256507; CS-7812; DB00908; MCULE-7178915526; NC00478; SDCCGMLS-0066600.P001; NCGC00091231-01; NCGC00091231-02; NCGC00091231-03; AS-30538; AB00514657; 6470-EP1441224A2; 6470-EP2272835A1; 6470-EP2272844A1; 6470-EP2272972A1; 6470-EP2272973A1; 6470-EP2275411A2; 6470-EP2277872A1; 6470-EP2305655A2; 6470-EP2314576A1; 6470-EP2314585A1; M-7594; AB01562940_01; Q412496; W-109256; BRD-K59632282-052-01-5; BRD-K59632282-052-02-3; BRD-K70799801-311-02-7; Quinidine, crystallized, >=98.0% (dried material, NT); 101143-86-6
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Supraventricular tachyarrhythmia [ICD-11: BC81] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C20H24N2O2
|
|||
| PubChem CID | ||||
| Canonical SMILES |
COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
|
|||
| InChI |
1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
|
|||
| InChIKey |
LOUPRKONTZGTKE-LHHVKLHASA-N
|
|||
| CAS Number |
CAS 56-54-2
|
|||
| ChEBI ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
| Cinchonine | Cinchona calisaya | Click to Show/Hide the Molecular Data of This NP | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MES-SA | CVCL_1404 | Uterine corpus sarcoma | Homo sapiens | ||
| MES-SA/Dx5 | CVCL_2598 | Uterine corpus sarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Hydrocinchonine exerted MDR reversal activity and synergistic apoptotic effect with TAX in MES-SA/DX5 cells almost comparable with quinidine and cinchonine as a potent MDR-reversal and combined therapy agent with TAX. | |||||
